ArticleJournal of translational medicine2025
Integrated spatial metabolomics and transcriptomics reveal the molecular landscape of papillary thyroid cancer and its lymph node metastasis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-state transitions and microenvironmental remodeling in thyroid cancer progression revealed by single-cell and spatial transcriptomics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPapillary thyroid cancer (PTC) exhibits highly variable clinical behavior, ranging from indolent growth to aggressive lymph node (LN) metastasis. However, the specific molecular mechanisms involved in PTC evolution, driven by metabolic reprogramming and tumor-microenvironmental interactions, remain poorly understood. This study aims to elucidate the spatial metabolic and transcriptional mechanisms underlying PTC tumorigenesis and LN metastasis at multiple molecular levels.
methodsAn integrated spatial multi-omics strategy combining spatial metabolomics and spatial transcriptomics was employed to map the distribution of metabolites and gene expression in heterogeneous PTC tissues. Metabolite profiles and transcriptomic data were analyzed to identify dysregulated pathways and to uncover the key molecular features contributing to PTC tumorigenesis and LN metastasis. Genes related to metastasis-driving metabolites were validated using the TCGA dataset, and further substantiated by zebrafish xenograft models.
resultsSpatial mapping revealed unique metabolic and transcriptional signatures across heterogeneous regions of PTC tissue. Key metabolic pathways, such as the arginine-polyamine axis, glycolysis and lipid metabolism, were prominently dysregulated in cancer regions. The surrounding stroma also exhibited metabolic adaptations, like polyamine recycling and glucose storage, which supported tumor growth via metabolic crosstalk. Most importantly, greater spatial heterogeneity, spatial evolutionary routes and 5 potential metastasis-driving metabolites, including FA (22:6), PC (36:4), PC (34:1), N-acetylaspartate and ascorbic acid, were discovered in the primary PTC tissue with LN metastasis. Knockdown of key genes NAT8L and SVCT-2 obviously decreased the metastatic ability of PTC cells. The TCGA database further confirmed that high expression of 10 pro-metastatic metabolite-related genes was significantly associated with poorer prognosis in PTC patients.
conclusionsThis integrated spatial multi-omics approach provides novel insights into the molecular mechanisms underlying PTC evolution, potentially guiding the development of more effective diagnostic and therapeutic strategies for PTC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.